Clinical trial
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic…
NCT00477464 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00477464 |
|---|---|
| Title | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer |
| Official title | Clinical Evaluation of Lapatinib Administered With Capecitabine in Japanese Patients With ErbB2 Overexpressing Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Lapatinib, capecitabine |
| Enrollment | 51 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | May 23, 2007 |
| Last update posted | Sep 17, 2018 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: